



Pharmaceuticals —

Pipeline Overview and Progress

November 6, 2023 –
Investor Relations



Pharmaceuticals – Pipeline Overview¹ (as of Nov 6, 2023)

Phase 0 ²	Phase I	Phase II	Phase III
PSMA SMOL TAC (BAY 3563254) ●	AhR Inhibitor (BAY 2416964) ●	Regorafenib (combi Nivolumab) (BAY 734506) ○	Darolutamide (AR Inhibitor) ○
VVD STAT3 Inh (BAY 3630914) ●	mEGFR Inhibitor (BAY 2927088) ●	Asundexian (FXIa Inhibitor) (BAY 2433334) ●	Finerenone (MR Antagonist) ○
Next Generation Liver MRI (BAY 3393081) ●	DGKzeta Inhibitor (BAY 2965501) ●	Zabedoseritib (IRAK4 Inh.) (BAY 1834845) ●	Vericiguat (sGC Stimulator) ○
	CCR8 Ab (BAY 3375968) ●	Runcaciguat (sGC Activator) (BAY 1101042) ●	Asundexian (FXIa Inhibitor) ●
	VVD KEAP1 Act (VVD-13307 aka NRF2 Inh, BAY 3605349) ●		Elinzanetant (Neurokinin-1,3 Rec Antagonist) ●
	DGKalpha Inh (BAY 2862789) ●		Aflibercept 8mg (VEGF Inhibitor) ○
	PSMA TAC (BAY 3546828) ●		Gadoquatrane (High Relaxivity Contrast Agent) ●
	Congestive Heart Failure rAAV Gene Therapy (AB-1002 aka NAN-101) ●		
	sGC Activator Oral (BAY 3283142) ●		
	Anti-a2AP (BAY 3018250) ●		
	SEMA 3a (BAY 3401016) ●		
	Anti-coagulant (BAY 3389934) ●		
	Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01) ●		
	Parkinson's Disease rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-PD) ●		
	Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA) ●		
	Pompe Disease rAAV Gene Therapy (ACTUS-101) ●		
	Huntington's Disease rAAV Gene Therapy (AB-1001 aka BV-101) ●		
	LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101) ●		
	GPR84 Antagonist (BAY 3178275) ●		
	BAY 2701250 ●		

Submissions
Aflibercept 8mg (VEGF-Inhibitor) ○
EU, JP: Diabetic Macular Edema (DME)
EU, JP, CN: Neovasc. Age-rel. Macular Degen. (nAMD)

- Oncology
- Cardiovascular+⁴
- Neurology & Rare Diseases
- Immunology
- Others
- New molecular entity
- Life cycle management



¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
² Pre-clinical selected assets on path to IND ³ Conducted by Merck & Co ⁴ Including Precision Cardiovascular, Nephrology & Acute Care
 2 /// Bayer Pharmaceuticals /// Pipeline Overview November 6, 2023



Pharmaceuticals – Pipeline Details Phase III¹ (as of Nov 6, 2023)

Therapeutic Area	Candidate medication	Modality	Compound Origin	Indication	Ct.gov Identifier	Estimated/actual primary completion	Status
Oncology	Darolutamide (AR Inhibitor)		Orion	Prostate Cancer (mHSPC) (<i>ARANOTE</i>)	NCT04736199	Q1 2024	Study ongoing
				Adjuvant Prostate Cancer (<i>DASL-HiCaP</i>)	NCT04136353	Q1 2028	Study ongoing
				Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (<i>ARASTEP</i>)	NCT05794906	Q1 2027	Study ongoing
Cardiovascular+ ³	Finerenone (MR Antagonist)		Bayer	Heart Failure (HFmr/pEF) (<i>FINEARTS-HF</i>)	NCT04435626	Q2 2024	Study ongoing
				Non-diabetic CKD (<i>FIND-CKD</i>)	NCT05047263	Q1 2026	Study ongoing
	Vericiguat (sGC Stimulator)		Bayer	Heart Failure (HFrEF) (<i>VICTOR²</i>)	NCT05093933	Q1 2025	Study ongoing
	Asundexian (FXIa Inhibitor)		Bayer	Stroke Prevention in Atrial Fibrillation (<i>OCEANIC-AF</i>)	NCT05643573	Q3 2025	Study ongoing
2° Stroke Prevention (<i>OCEANIC-STROKE</i>)				NCT05686070	Q4 2025	Study ongoing	
Others	Elinzanetant (Neurokinin-1,3 Rec Antagonist)		KaNdy	Vasomotor Symptoms (<i>OASIS-1, OASIS-2, OASIS-3, OASIS-4</i>)	NCT05042362 NCT05099159 NCT05030584 NCT05587296	Q3 2023 Q2 2023 Q1 2023 Q1 2024	Study ongoing Study completed Study ongoing Study ongoing
	Aflibercept 8mg (VEGF Inhibitor)		Regeneron	Retinal Vein Occlusion (RVO) (<i>QUASAR</i>)	NCT05850520	Q4 2024	Study ongoing
	Gadoquatrane (High Relaxivity Contrast Agent)		Bayer	Magnetic Resonance Imaging (<i>QUANTI-CNS, QUANTI-OB</i>)	NCT05915702 NCT05915728	Q4 2024 Q4 2024	Studies ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Conducted by Merck & Co
³ Including Precision Cardiovascular, Nephrology & Acute Care



Pharmaceuticals – Pipeline Details Phase II¹ (as of Nov 6, 2023)

Therapeutic Area	Candidate medication	Modality	Compound Origin	Indication	Ct.gov Identifier	Estimated/actual primary completion	Status
Oncology	Regorafenib (combi Nivolumab) (BAY 734506)		Bayer	Solid tumors (recurrent or metastatic)	NCT04704154	Q1 2023	Study ongoing
Cardiovascular+ ²	Asundexian (FXIa Inhibitor) (BAY 2433334)		Bayer	Major Adverse Cardiac Events Prevention (PACIFIC-AMI)	NCT04304534	Q1 2022	Study completed
Immunology	Zabedoseritib (IRAK4 Inhibitor) (BAY 1834845)		Bayer	Atopic Dermatitis (DAMASK)	NCT05656911	Q4 2023	Study ongoing
Others	Runcaciguat (sGC Activator) (BAY 1101042)		Bayer	Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR)	NCT04722991	Q2 2024	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Including Precision Cardiovascular, Nephrology & Acute Care



Pharmaceuticals – Pipeline Details Phase I¹ (as of Nov 6, 2023)

Therapeutic Area	Candidate medication	Modality	Compound Origin	Indication	Ct.gov Identifier	Estimated/actual primary completion	Status
Oncology	AhR Inhibitor (BAY 2416964)		Bayer/DKFZ	Advanced solid tumors	NCT04069026 NCT04999202	Q1 2024 Q4 2025	Studies ongoing
	mEGFR Inhibitor (BAY 2927088)		Bayer/Broad Institute	Adv. Non-small Cell Lung Cancer w EGFR Mut. and/or HER2 Mut.	NCT05099172	Q3 2028	Study ongoing
	DGKzeta Inhibitor (BAY 2965501)		Bayer/DKFZ	Advanced solid tumors	NCT05614102	Q3 2026	Study ongoing
	CCR8 Ab (BAY 3375968)		Bayer	Advanced solid tumors	NCT05537740	Q4 2026	Study ongoing
	VVD KEAP1 Act (VVD-13307 aka NRF2 Inh, BAY 3605349)		Vividion	Advanced solid tumors	NCT05954312	Q4 2027	Study ongoing
	DGKalpha Inhibitor (BAY 2862789)		Bayer/DKFZ	Advanced solid tumors	NCT05858164	Q1 2026	Study ongoing
	PSMA TAC (BAY 3546828)		Lantheus	Advanced Prostate Cancer	NCT06052306	Q2 2027	Study ongoing
Cardiovascular+ ²	Congestive Heart Failure rAAV Gene Therapy (AB-1002 aka NAN-101)		AskBio	Congestive Heart Failure	NCT04179643	Q4 2023	Study ongoing
	sGC Activator (BAY 3283142)		Bayer	Chronic Kidney Disease (CKD)	NCT05491642	Q1 2023	Study completed
	Anti-a2AP (BAY 3018250)		Bayer	Acute Ischemic Stroke; Pulmonary Embolism	n/a	Q2 2023	Study ongoing
	SEMA 3a (BAY 3401016)		Bayer/Evotec	Alport Syndrome	n/a	Q3 2024	Study ongoing
	Anti-coagulant (BAY 3389934)		Bayer	Anti-coagulation	n/a	Q2 2024	Study ongoing
Neurology / Rare Diseases	Bemdaneprocel (Parkinson's Disease Cell Therapy) (BRT-DA01)		BlueRock	Parkinson's Disease	NCT04802733	Q2 2023	Study ongoing, detailed Phase I trial data will be presented at the International Congress on Parkinson's Disease and Movement Disorders in Aug 2023
	Parkinson's Disease rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-PD)		AskBio	Parkinson's Disease	NCT04167540	Q4 2023	Study ongoing
	Multiple System Atrophy rAAV Gene Therapy (AB-1005 aka AAV2-GDNF-MSA)		AskBio	Multiple System Atrophy	NCT04680065	Q4 2025	Study ongoing
	Pompe Disease rAAV Gene Therapy (ACTUS-101)		AskBio	Pompe Disease	NCT03533673	Q3 2022	Study ongoing
	Huntington's Disease rAAV Gene Therapy (AB-1001 aka BV-101)		AskBio	Huntington's Disease	NCT05541627	Q4 2025	Study ongoing
	LGMD2I/R9 rAAV Gene Therapy (AB-1003 aka LION-101)		AskBio	Limb Girdle Muscular Dystrophy	NCT05230459	Q4 2028	Study ongoing
Others	GPR84 Antagonist (BAY 3178275)		Bayer	Diabetic Neuropathic Pain	n/a	Q1/2024	Study ongoing
	BAY 2701250		Bayer	Pulmonary Hypertension	NCT06048120	Q1 2025	Study ongoing

¹ 1 Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Including Precision Cardiovascular, Nephrology & Acute Care





Pharmaceuticals – Pipeline Details Oncology¹ (as of Nov 6, 2023)

Candidate medication	Indication	Modality	Compound Origin	Phase 0 ²	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/actual primary completion	Status
Darolutamide (AR Inhibitor)	Prostate Cancer (mHSPC) (ARANOTE)		Orion					NCT04736199	Q1 2024	Study ongoing
	Adjuvant Prostate Cancer (DASL-HiCaP)							NCT04136353	Q1 2028	Study ongoing
	Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)							NCT05794906	Q1 2027	Study ongoing
Regorafenib (combi Nivolumab) (BAY 734506)	Solid tumors (recurrent or metastatic)		Bayer					NCT04704154	Q1 2023	Study ongoing
AhR Inhibitor (BAY 2416964)	Advanced solid tumors		Bayer/DKFZ					NCT04069026 NCT04999202	Q1 2024 Q4 2025	Studies ongoing
mEGFR Inhibitor (BAY 2927088)	Advanced Non-small Cell Lung Cancer with EGFR Mutation and/or HER2 Mutation		Bayer/Broad Institute					NCT05099172	Q3 2028	Study ongoing
DGKzeta Inhibitor (BAY 2965501)	Advanced solid tumors		Bayer/DKFZ					NCT05614102	Q3 2026	Study ongoing
CCR8 Ab (BAY 3375968)	Advanced solid tumors		Bayer					NCT05537740	Q4 2026	Study ongoing
VVD KEAP1 Act (VVD-13307 aka NRF2 Inh, BAY 3605349)	Advanced solid tumors		Vividion					NCT05954312	Q4 2027	Study ongoing
DGKalpha Inh (BAY 2862789)	Cancer		Bayer/DKFZ					NCT05858164	Q1 2026	Study ongoing
PSMA TAC (BAY 3546828)	Advanced Prostate Cancer		Lantheus					NCT06052306	Q2 2027	Study ongoing
PSMA SMOL TAC (BAY 3563254)	Advanced Prostate Cancer		NoriaThx/PSMA Thx							
VVD STAT3 Inh (BAY 3630914)	Cancer		Vividion							

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND





Pharmaceuticals – Pipeline Details Cardiovascular+^{1,4} (as of Nov 6, 2023)

Candidate medication	Indication	Modality	Compound Origin	Phase 0 ²	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/actual primary completion	Status	
Finerenone (MR Antagonist)	Heart Failure (HFmr/pEF) (<i>FINEARTS-HF</i>)		Bayer					NCT04435626	Q2 2024	Study ongoing	
	Non-diabetic CKD (<i>FIND-CKD</i>)								NCT05047263	Q1 2026	Study ongoing
Vericiguat (sGC Stimulator)	Heart Failure (HFrEF) (<i>VICTOR</i> ³)		Bayer					NCT05093933	Q1 2025	Study ongoing	
Asundexian (FXIa Inhibitor) (<i>BAY 2433334</i>)	Stroke Prevention in Atrial Fibrillation (<i>OCEANIC-AF</i>)		Bayer					NCT05643573	Q3 2025	Study ongoing	
	2 ^o Stroke Prevention (<i>OCEANIC-STROKE</i>)								NCT05686070	Q4 2025	Study ongoing
	Major Adverse Cardiac Events Prevention (<i>PACIFIC-AMI</i>)								NCT04304534	Q1 2022	Study completed
Congestive Heart Failure rAAV Gene Therapy (<i>AB-1002 aka NAN-101</i>)	Congestive Heart Failure		AskBio					NCT04179643	Q4 2023	Study ongoing	
sGC Activator (<i>BAY 3283142</i>)	Chronic Kidney Disease (CKD)		Bayer					NCT05491642	Q1 2023	Study completed	
Anti-a2AP (<i>BAY 3018250</i>)	Acute Ischemic Stroke; Pulmonary Embolism		Bayer					n/a	Q2 2023	Study ongoing	
SEMA 3a (<i>BAY 3401016</i>)	Alport Syndrome		Bayer/Evotec					n/a	Q3 2024	Study ongoing	
Anti-coagulant (<i>BAY 3389934</i>)	Anti-coagulation		Bayer					n/a	Q2 2024	Study ongoing	

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND ³ Conducted by Merck & Co ⁴ Including Precision Cardiovascular, Nephrology & Acute Care







Pharmaceuticals – Pipeline Details Neurol./Rare Dis.¹ (as of Nov 6, 2023)

Candidate medication	Indication	Modality	Compound Origin	Phase 0 ²	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/actual primary completion	Status
Bemdaneprocel (Parkinson's Disease Cell Therapy) (<i>BRT-DA01</i>)	Parkinson's Disease		BlueRock					NCT04802733	Q2 2023	Study ongoing, detailed Phase I trial data will be presented at the International Congress on Parkinson's Disease and Movement Disorders in Aug 2023
Parkinson's Disease rAAV Gene Therapy (<i>AB-1005 aka AAV2-GDNF-PD</i>)	Parkinson's Disease		AskBio					NCT04167540	Q4 2023	Study ongoing
Multiple System Atrophy rAAV Gene Therapy (<i>AB-1005 aka AAV2-GDNF-MSA</i>)	Multiple System Atrophy		AskBio					NCT04680065	Q4 2025	Study ongoing
Pompe Disease rAAV Gene Therapy (<i>ACTUS-101</i>)	Pompe Disease		AskBio					NCT03533673	Q3 2022	Study ongoing
Huntington's Disease rAAV Gene Therapy (<i>AB-1001 aka BV-101</i>)	Huntington's Disease		AskBio					NCT05541627	Q4 2025	Study ongoing
LGMD2I/R9 rAAV Gene Therapy (<i>AB-1003 aka LION-101</i>)	Limb-Girdle Muscular Dystrophy 2i		AskBio					NCT05230459	Q4 2028	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND



Pharmaceuticals – Pipeline Details Immunology¹ (as of Nov 6, 2023)

Candidate medication	Indication	Modality	Compound Origin	Phase 0 ²	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/actual primary completion	Status
Zabedoseritib (IRAK4 Inhibitor) (BAY 1834845)	Atopic Dermatitis (DAMASK)		Bayer					NCT05656911	Q4 2023	Study ongoing

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND



Pharmaceuticals – Pipeline Details Others¹ (as of Nov 6, 2023)

Candidate medication	Indication	Modality	Compound Origin	Phase 0 ²	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/actual primary completion	Status
Elinzanetant (Neurokinin-1,3 Rec Antagonist)	Vasomotor Symptoms (OASIS-1, OASIS-2, OASIS-3, OASIS-4)		KaNDy					NCT05042362 NCT05099159 NCT05030584 NCT05587296	Q3 2023 Q2 2023 Q1 2023 Q1 2024	Study ongoing Study completed Study ongoing Study ongoing
Aflibercept 8mg (VEGF Inhibitor)	Retinal Vein Occlusion (RVO) (QUASAR)		Regeneron					NCT05850520	Q4 2024	Study ongoing
Gadoquatrane (High Relaxivity Contrast Agent, HRCA)	Magnetic Resonance Imaging (QUANTI-CNS, QUANTI-OBR)		Bayer					NCT05915702 NCT05915728	Q4 2024 Q4 2024	Studies ongoing
Runcaciguat (sGC Activator) (BAY 1101042)	Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR)		Bayer					NCT04722991	Q2 2024	Study ongoing
GPR84 Antagonist (BAY 3178275)	Diabetic Neuropatic Pain		Bayer					n/a	Q1 2024	Study ongoing
BAY 2701250	Pulmonary Hypertension		Bayer					NCT06048120	Q1 2025	Study ongoing
Next Generation Liver MRI (BAY 3393081)	Contrast Media		Bayer					n/a		

¹ Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit ² Pre-clinical selected assets on path to IND